Search Results - "Karlan, B Y"

Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment by Taylor-Harding, B, Agadjanian, H, Nassanian, H, Kwon, S, Guo, X, Miller, C, Karlan, B Y, Orsulic, S, Walsh, C S

“…Background: Bortezomib is a proteasome inhibitor with minimal clinical activity as a monotherapy in solid tumours, but its combination with other targeted…”
Get full text

Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin by Wolf, I, Laitman, Y, Rubinek, T, Abramovitz, L, Novikov, I, Beeri, R, Kuro-O, M, Koeffler, H P, Catane, R, Freedman, L S, Levy-Lahad, E, Karlan, B Y, Friedman, E, Kaufman, B

“…Klotho is a transmembrane protein that can be shed and act as a circulating hormone and is a putative tumor suppressor in breast cancer. A functional variant…”
Get full text

BRCA1 promoter region hypermethylation in ovarian carcinoma : A population-based study by BALDWIN, Rae Lynn, NEMETH, Elizabeta, HANG TRAN, SHVARTSMAN, Hyun, CASS, Ilana, NAROD, Steven, KARLAN, Beth Y

“…There is a clear association between germ-line BRCA1 mutations and inherited ovarian cancer; however, the association between BRCA1 mutations and sporadic…”
Get full text

Cyclin E as a potential therapeutic target in high grade serous ovarian cancer by Kanska, J, Zakhour, M, Taylor-Harding, B, Karlan, B.Y, Wiedemeyer, W.R

“…Abstract Cyclin E1 ( CCNE1 ) gene amplification occurs in approximately 20% of ovarian high grade serous carcinoma (HGSC) and is associated with chemotherapy…”
Get full text

Survival Impact of Surgical Cytoreduction in Stage IV Epithelial Ovarian Cancer by Bristow, Robert E., Montz, Fredrick J., Lagasse, Leo D., Leuchter, Ronald S., Karlan, Beth Y.

“…Objective.The aim of this study was to evaluate the influence of surgical cytoreduction on survival in patients with Stage IV epithelial ovarian cancer and to…”
Get full text

Differential gene expression between normal and tumor-derived Ovarian epithelial cells by ISMAIL, Rubina S, BALDWIN, Rae Lynn, JUNGUO FANG, BROWNING, Damaris, KARLAN, Beth Y, GASSON, Judith C, CHANG, David D

“…The majority of ovarian tumors arise from the transformation of the ovarian surface epithelial cells, a single layer of cells surrounding the ovary. To…”
Get full text

FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival by Memarzadeh, S, Holschneider, C H, Bristow, R E, Jones, N L, Fu, Y S, Karlan, B Y, Berek, J S, Farias-Eisner, R

“…The objective of this study was to assess the impact of surgical cytoreduction on the survival of patients with uterine papillary serous carcinoma (UPSC)…”
Get more information

Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer by Davidson, T.M., Lebreton, C.L., Hendricksen, A.E. Wahner, Atkinson, H.J., Larson, M.C., Oberg, A.L., Provencher, D.M., Glaspy, J.A., Karlan, B.Y., Slamon, D.J., Konecny, G.E., Ray-Coquard, I.L.

“…IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a…”
Get full text

Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy by Powell, C.B., Swisher, E.M., Cass, I., McLennan, J., Norquist, B., Garcia, R.L., Lester, J., Karlan, B.Y., Chen, L.

“…The reported incidence of neoplasia identified at the time of risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA1/2 mutation carriers ranges from 4 to…”
Get full text

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer by Konecny, G.E., Hendrickson, A.E. Wahner, Davidson, T.M., Winterhoff, B.J., Ma, S., Mahner, S., Sehouli, J., Fasching, P.A., Feisel-Schwickardi, G., Poelcher, M., Roman, L.D., Rody, A., Karlan, B.Y., Mullany, S.A., Chen, H., Ray-Coquard, I.L., Provencher, D.M., Yachnin, A., Cottu, P.H., Glaspy, J.A., Haluska, P., Slamon, D.J.

“…Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy…”
Get full text

Ovulation induction, infertility, and ovarian cancer risk by Bristow, R E, Karlan, B Y

“…To review critically the published data regarding the proposed association of ovulation induction, infertility, and an increased risk of ovarian cancer. A…”
Get more information

Foxc2 induces Wnt4 and Bmp4 expression during muscle regeneration and osteogenesis by Gozo, M C, Aspuria, P-J, Cheon, D-J, Walts, A E, Berel, D, Miura, N, Karlan, B Y, Orsulic, S

“…Proliferation and fusion of myoblasts is a well-orchestrated process occurring during muscle development and regeneration. Although myoblasts are known to…”
Get full text

Hormone receptor expression in uterine sarcomas: Prognostic and therapeutic roles by Ioffe, Y.J, Li, A.J, Walsh, C.S, Karlan, B.Y, Leuchter, R, Forscher, C, Cass, I

“…Abstract Objectives. The utility of hormone therapy in the management of uterine sarcomas is poorly defined. We hypothesize that estrogen receptor (ER)…”
Get full text

Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma by Karlan, B Y, Hawkins, R, Hoh, C, Lee, M, Tse, N, Cane, P, Glaspy, J

“…The existing means of detecting recurrent ovarian carcinoma are notoriously poor. Positron emission tomography (PET) is a form of computer-assisted imaging…”
Get more information

Vaginal high-grade sarcoma in pregnancy by Akametalu, P., Barcelon, J.M., Myint, O., Moatamed, N.A., Karlan, B.Y., Kamrava, M., Cohen, J.G.

“…•Vaginal sarcoma is rare in pregnancy.•Surgical excision is the mainstay of treatment.•Adjuvant radiation may improve local control in the management of…”
Get full text

Altered expression of transforming growth factor‐β ligands and receptors in primary and recurrent ovarian carcinoma by Bristow, Robert E., Baldwin, Rae Lynn, Yamada, S. Diane, Korc, Murray, Karlan, Beth Y.

“…BACKGROUND Resistance to the potent growth inhibitory effects of transforming growth factor‐β (TGF‐β) is a characteristic of many malignancies. TGF‐β…”
Get full text

Improved survival in women with BRCA‐associated ovarian carcinoma by Cass, Ilana, Baldwin, Rae Lynn, Varkey, Taz, Moslehi, Roxana, Narod, Steven A., Karlan, Beth Y.

“…BACKGROUND The objective of this study was to determine the clinical characteristics, treatment response, and frequency of p53 overexpression in Ashkenazi…”
Get full text

Overexpression of AKT2/Protein Kinase B beta Leads to Up-Regulation of beta 1 Integrins, Increased Invasion, and Metastasis of Human Breast and Ovarian Cancer Cells by Arboleda, MJ, Lyons, J F, Kabbinavar, F F, Bray, M R, Snow, B E, Ayala, R, Danino, M, Karlan, B Y, Slamon, D J

“…To determine how AKT2 might contribute to tumor cell progression, a full-length, wild-type, human AKT2/protein kinase B (PKB) beta cDNA was transfected into a…”
Get full text

Secondary surgical cytoreduction for advanced epithelial ovarian cancer: Patient selection and review of the literature by Bristow, Robert E., Lagasse, Leo D., Karlan, Beth Y.

“…BACKGROUND Standard therapy for advanced epithelial ovarian cancer now includes primary cytoreductive surgery followed by combination chemotherapy. Optimal…”
Get full text

Primary Ovarian Cancer Cultures are Resistant to Fas-Mediated Apoptosis by Baldwin, Rae Lynn, Tran, Hang, Karlan, Beth Y.

“…Objectives. Fas, a primary mediator of cellular apoptosis, is expressed by the normal ovarian epithelium. We analyzed the levels of Fas and soluble Fas (sFas)…”
Get full text